Allison A. Barraclough

Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: March 10, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances
Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances
Published: February 05, 2026

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood
Published: November 04, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood
Published: November 04, 2025

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL.

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL.

Journal: Blood neoplasia
Published: May 01, 2025

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Journal: Haematologica
Published: March 28, 2025

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

Journal: Blood advances
Published: March 14, 2025

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Journal: Journal of the National Cancer Institute
Published: January 07, 2025

Predicting bispecific antibody failure in diffuse large B-cell lymphoma.

Predicting bispecific antibody failure in diffuse large B-cell lymphoma.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 07, 2024

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma.

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma.

Journal: Blood
Published: November 27, 2024

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Journal: Blood advances
Published: November 27, 2024
Showing 1-12 of 39

Last Updated: 09/26/2026